In prostate cancer, a novel risk model comprising five genes, namely poly(rC) binding protein 1 (PCBP1), PABPN1, protein tyrosine phosphatase receptor type F (PTPRF), differentiation antagonizing non-protein-coding RNA (DANCR), and MYC, was established for predicting progression-free survival (PFS). This evidence concerns the gene PCBP1 and prostate cancer.